Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated non-small-cell lung cancer with no epidermal growth factor receptor - or anaplastic-lymphoma-kinase -positive mutations.
Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1143

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
11 October 2019 As you are aware the Department for Health and Social Care has asked NICE to carry out an appraisal of durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes
12 April 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations. However, following on from information received from the company regarding the recent results for the Phase III MYSTIC trial, the timelines for this appraisal are to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.
24 January 2018 - 21 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 June 2017 In progress. Topic referred
21 April 2017 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual